GeoVax and ViaMune to Collaborate on Cancer Immunotherapy Program

ATLANTA, GA (Marketwired Nov 7, 2016) GeoVax Labs, Inc. (OTCQB: GOVX) announced today its collaboration with ViaMune, Inc. for the co-development of each company s cancer immunotherapy programs. Both companies products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumor types. Due to overexpression and/or aberrant glycosylation of MUC1, this tumor-associated antigen (TAA) is often recognized as abnormal by patients immune system but is not sufficiently immunogenic

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: